MarketCapExport financials
Teladoc Health (TDOC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Teladoc Health Financial Ratios 2025-2011 | TDOC
Brief overview of Teladoc Health's financial ratios
The review covers five available annual periods spanning 2021 to 2025.
Key multiples at the end of the period are P/S 0.38x (median 0.92x), P/B 0.69x (median 0.97x), P/CF 3.24x (median 6.83x). On average, this basket is 52.6% below its own five-year medians. The market values the business at a discount to recent history.
The latest available business-quality ratios are ROE -14.5%, ROA -7%, ROCE -19%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
Price, earnings and growth produce a PEG of 1.83x. A high value reduces the cushion if growth slows.
The cash cycle accelerated by 12.3 days to 28.2 days. Less capital is tied up in operations.
Valuation takeaway
Teladoc Health's multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Teladoc Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-4.8 | -1.6 | -10.9 | -0.3 | -27.8 | -41.2 | -76.1 | -42.1 | -18.8 | -11.8 | -5.6 | - | - | - | - |
P/S |
0.4 | 0.6 | 0.9 | 1.7 | 5.9 | 18.3 | 13.6 | 9.8 | 8.6 | 7.1 | 4.2 | - | - | - | - |
EPS |
-1.1 | -5.9 | -1.3 | -84.6 | -2.7 | -5.4 | -1.4 | -1.5 | -1.9 | -1.8 | -2.9 | -10.2 | -8.1 | - | - |
EV (Enterprise Value) |
1.64 B | 2.36 B | 3.33 B | 3.29 B | 11 B | 19.3 B | 7.6 B | 4.18 B | 2.23 B | 899 M | 320 M | -7.66 M | 5.12 M | - | - |
EBITDA per Share |
0.5 | -3.85 | 0.47 | -83 | -0.45 | -4.83 | -0.485 | -0.461 | -0.778 | -1.12 | -2.56 | - | - | - | - |
EV/EBITDA |
18.7 | -3.6 | 43.1 | -0.2 | -177.2 | -99.0 | -213.7 | -134.3 | -50.5 | -18.4 | -5.8 | - | - | - | - |
PEG |
-0.0 | -0.0 | -0.0 | -0.0 | -0.19 | -0.27 | -12.43 | -1.77 | 1.83 | -0.3 | 0.02 | - | - | - | - |
P/B |
0.7 | 1.1 | 1.0 | 1.0 | 0.7 | 1.1 | 7.4 | 4.0 | 3.6 | 3.8 | 1.8 | - | - | - | - |
P/CF |
3.2 | 5.6 | 6.8 | 22.2 | 61.4 | -374.0 | 396.7 | -308.1 | -50.4 | -15.9 | -5.9 | - | - | - | - |
ROE % |
-14.46 | -67.15 | -9.47 | -591.90 | -2.67 | -3.05 | -9.75 | -9.58 | -19.11 | -32.15 | -32.49 | - | - | - | - |
ROA % |
-7.01 | -28.47 | -5.02 | -314.35 | -2.42 | -2.73 | -6.17 | -6.35 | -12.95 | -24.44 | -25.25 | - | - | - | - |
ROCE % |
-18.98 | -68.47 | -10.69 | -591.63 | -1.66 | -3.19 | -4.88 | -4.50 | -7.93 | -19.71 | -26.34 | - | - | - | - |
Current Ratio |
1.9 | 1.7 | 2.1 | - | - | - | 6.5 | 8.5 | 3.9 | 3.9 | 8.4 | - | - | - | - |
DSO |
29.4 | 30.7 | 30.0 | 28.8 | 30.4 | 37.7 | 37.6 | 38.1 | 42.4 | 40.9 | 57.2 | - | - | - | - |
DIO |
18.1 | 16.4 | 20.6 | 31.7 | 36.4 | 26.4 | - | - | - | - | - | - | - | - | - |
DPO |
19.2 | 18.6 | 21.9 | 23.3 | 26.2 | 25.7 | 18.0 | 22.0 | 23.0 | 25.5 | 38.4 | - | - | - | - |
Operating Cycle |
47.4 | 47.1 | 50.6 | 60.5 | 66.7 | 64.1 | 37.6 | 38.1 | 42.4 | 40.9 | 57.2 | - | - | - | - |
Cash Conversion Cycle |
28.2 | 28.4 | 28.7 | 37.2 | 40.5 | 38.4 | 19.6 | 16.0 | 19.4 | 15.4 | 18.8 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Teladoc Health
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.21 | -0.36 | -0.28 | -0.19 | -0.53 | - | -0.19 | -4.92 | -0.49 | - | -0.35 | -0.4 | -0.42 | - | -0.45 | -19.22 | -41.58 | - | -0.53 | -0.86 | -1.31 | - | -0.43 | -0.34 | -0.4 | -0.26 | -0.28 | -0.41 | -0.43 | -0.35 | -0.34 | -0.4 | -0.39 | -0.76 | -0.55 | -0.28 | -0.3 | -0.31 | -0.65 | -0.38 | -0.4 | - | -0.37 | -7.2 | -5.87 | - | -2.68 | -2.15 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.28 | 0.16 | 0.19 | 0.19 | -0.21 | - | 0.25 | -4.38 | 0.05 | - | 0.16 | 0.01 | -0.06 | - | -0.06 | -18.8 | -41.2 | - | 0.57 | -0.18 | -0.24 | - | 0.15 | 0.16 | -0.15 | -0.08 | 0.19 | 0.01 | -0.16 | -0.12 | -0.09 | -0.16 | -0.18 | -0.29 | -0.27 | -0.22 | -0.23 | -0.23 | -0.38 | -0.33 | -0.34 | - | -0.31 | -6.47 | -5.41 | - | -1.56 | -1.17 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-13.60 | -17.15 | -14.58 | -66.79 | -68.07 | -61.55 | -64.04 | -64.67 | -11.93 | -8.35 | -9.56 | -58.05 | -128.21 | -125.19 | -125.72 | -125.34 | -75.63 | -2.63 | -2.85 | -2.49 | -1.84 | -0.57 | -2.45 | -4.23 | -6.96 | -9.75 | -10.33 | -10.62 | -10.20 | -9.58 | -15.07 | -18.38 | -18.66 | -19.11 | -17.34 | -24.63 | -28.32 | -32.15 | -33.39 | -30.05 | -30.72 | -24.09 | -17.38 | -5.23 | -7.11 | - | 6.71 | 4.74 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-6.53 | -7.82 | -6.49 | -28.54 | -29.31 | -26.61 | -27.93 | -28.50 | -6.33 | -4.44 | -5.34 | -64.20 | -63.16 | -61.56 | -62.32 | -61.41 | -62.55 | -2.37 | -2.58 | -2.24 | -1.65 | -0.51 | -1.70 | -2.77 | -4.45 | -6.17 | -6.61 | -6.86 | -6.67 | -6.35 | -10.11 | -12.39 | -12.61 | -12.95 | -12.27 | -18.27 | -21.30 | -24.44 | -25.51 | -23.13 | -23.76 | -18.72 | -23.65 | -21.36 | -5.53 | - | -4.92 | -3.48 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-15.01 | -20.63 | -18.95 | -71.22 | -71.20 | -62.75 | -65.57 | -65.75 | -13.11 | -9.31 | -10.49 | -58.56 | -128.39 | -125.02 | -125.40 | -124.71 | -74.36 | -1.41 | -1.53 | -1.20 | -0.84 | -0.30 | -1.84 | -3.68 | -5.81 | -7.93 | -8.16 | -7.75 | -7.37 | -6.99 | -9.63 | -11.92 | -12.73 | -13.49 | -14.83 | -19.75 | -23.42 | -27.14 | -28.47 | -28.79 | -29.58 | -23.21 | -17.50 | -6.21 | -7.05 | - | 5.71 | 4.23 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.9 | 1.9 | 1.9 | 2.0 | 1.7 | 1.7 | 1.8 | 1.7 | - | 2.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
32.7 | 31.5 | 31.8 | 33.1 | 32.4 | - | 30.7 | 30.7 | 30.5 | - | 29.1 | 30.1 | 30.9 | - | 15.1 | 14.8 | 29.1 | - | 31.3 | 32.4 | 35.0 | - | 53.5 | 64.1 | 57.1 | 33.2 | 37.7 | 39.9 | 35.7 | 32.4 | 35.8 | 42.0 | 36.0 | 32.0 | 36.0 | 55.4 | 43.5 | 33.7 | 38.9 | 47.6 | 44.0 | - | 55.4 | 60.6 | 52.5 | - | 57.2 | 30.3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
14.4 | 16.5 | 19.0 | 18.2 | 17.6 | - | 18.2 | 16.3 | 14.5 | - | 17.2 | 19.1 | 24.5 | - | 14.6 | 17.7 | 35.1 | - | 30.8 | 32.8 | 35.9 | - | 49.2 | 56.8 | 35.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
19.8 | 22.5 | 26.0 | 25.5 | 19.8 | - | 23.8 | 22.8 | 19.1 | - | 10.3 | 13.1 | 20.7 | - | 17.4 | 11.8 | 23.1 | - | 20.7 | 21.8 | 25.1 | - | 40.1 | 46.3 | 34.7 | 15.0 | 19.4 | 19.9 | 17.2 | 17.7 | 20.8 | 25.6 | 19.8 | 15.6 | 21.2 | 35.4 | 23.0 | 20.4 | 28.7 | 29.6 | 25.6 | - | 45.0 | 42.1 | 38.2 | - | 93.8 | 49.7 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 51.3 | 50.1 | - | 48.9 | 47.0 | 45.0 | - | 46.3 | 49.3 | 55.4 | - | 29.6 | 32.4 | 64.2 | - | 62.0 | 65.3 | 70.8 | - | 102.7 | 120.9 | 92.7 | 33.2 | 37.7 | 39.9 | 35.7 | 32.4 | 35.8 | 42.0 | 36.0 | 32.0 | 36.0 | 55.4 | 43.5 | 33.7 | 38.9 | 47.6 | 44.0 | - | 55.4 | 60.6 | 52.5 | - | 57.2 | 30.3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 25.8 | 30.3 | - | 25.1 | 24.3 | 25.9 | - | 36.0 | 36.2 | 34.7 | - | 12.2 | 20.6 | 41.1 | - | 41.3 | 43.5 | 45.7 | - | 62.6 | 74.6 | 58.0 | 18.2 | 18.3 | 20.0 | 18.5 | 14.7 | 15.1 | 16.4 | 16.2 | 16.4 | 14.8 | 20.1 | 20.5 | 13.3 | 10.2 | 17.9 | 18.5 | - | 10.4 | 18.4 | 14.3 | - | -36.5 | -19.4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Teladoc Health, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
American Well Corporation
AMWL
|
$ 13.97 | 5.91 % | $ 224 M |  USA |
 |
Evolent Health
EVH
|
$ 4.83 | -0.82 % | $ 552 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Omnicell
OMCL
|
$ 36.34 | -0.41 % | $ 1.67 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.37 | 4.93 % | $ 174 M | USA |
 |
Phreesia
PHR
|
$ 12.26 | 1.78 % | $ 732 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.57 | 1.42 % | $ 1.27 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.74 | -0.57 % | $ 122 M | USA |
 |
So-Young International
SY
|
$ 2.19 | -3.1 % | $ 171 M |  China |
 |
HealthEquity
HQY
|
$ 97.88 | 1.33 % | $ 8.43 B | USA |
 |
Veeva Systems
VEEV
|
$ 320.55 | 0.59 % | $ 52.5 B | USA |
 |
Schrödinger
SDGR
|
$ 23.9 | 2.14 % | $ 1.76 B | USA |
 |
Zhongchao
ZCMD
|
$ 1.34 | -4.96 % | $ 4.58 M | China |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 33.51 | -0.77 % | $ 1.01 B | USA |
 |
Progyny
PGNY
|
$ 28.44 | -0.49 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
$ 75.59 | 5.78 % | $ 9.43 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |